Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
Invivyd, Inc. (IVVD)
Company Research
Source: GlobeNewswire
Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody adintrevimabCompany anticipates submitting a COVID-19 treatment EUA application for PEMGARDA™ (pemivibart) imminentlyCOVID-19 treatment EUA pathway offers a novel, rapid pathway to potential second EUA for pemivibartInvivyd leaves 2024 net product revenue and year-end cash guidance unchanged although potential near-term COVID-19 treatment EUA and associated commercial dynamics were not considered Further details on upcoming 1Q 2024 results call on May 9, 2024 WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced its intention to submit an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for pemivibart for
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd, Inc. (NASDAQ: IVVD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference [Yahoo! Finance]Yahoo! Finance
- Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswire
- Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 5/9/24 - Beat
IVVD
Sec Filings
- 5/16/24 - Form 144
- 5/9/24 - Form S-8
- 5/9/24 - Form 10-Q
- IVVD's page on the SEC website